JMA Journal

Figure 1. RET rearrangement is detected in papillary thyroid cancer (PTC) and non-small cell lung cancer (NSCLC). RET/PTC1 and RET/PTC3 were reported to be detected in 5%–35% of adult and 60%–70% of childhood PTCs after the Chernobyl reactor accident, respectively. KIF5B-RET was identified mainly in NSCLC. SP, signal peptide; CLD, cadherin-like domain; CRD, cysteine-rich domain; TM, transmembrane domain; TK, tyrosine kinase domain.

Figure 2. RET missense mutations were identified in multiple endocrine neoplasia 2A (MEN2A) and 2B (MEN2B) and familial medullary thyroid carcinoma (FMTC).

Figure 3. RET missense mutations identified in Hirschsprung’s disease.